Navigation Links
Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Date:8/22/2007

ingham, added "VLPs represent an exciting new vaccine delivery platform for HIV, the full potential of which has not yet been realized."

Novavax will support its collaborators in completing pre-clinical studies of the consensus envelope HIV-1 VLP candidate vaccine over the next 12 - 18 months and human clinical trials could begin as early as 2009.

Novavax is developing vaccines to prevent influenza, HIV and other viral diseases leveraging its proprietary VLP vaccine technology. The company is conducting a Phase I/IIa clinical trial of a pre-pandemic influenza VLP vaccine.

About Novavax

Novavax Inc. (Nasdaq: NVAX) is a clinical-stage vaccine company committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventives options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, safety, efficacy and potency of our vaccines, and supply availability ar
'/>"/>

SOURCE Novavax, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
2. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
3. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
4. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
5. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
6. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
7. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
8. MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007
9. Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
10. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
11. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)...wswire-USNewswire/ -- Abnormalities in auditory an... with autism spectrum disorder by using magnetoenc... today at the annual meeting of the Radiological S...MEG, we can record the tiny magnetic fields associ... Roberts, Ph.D., vice chair of research in the Dep...
(Date:11/27/2008)...ajority of acute lymphoblastic leukemia relapse ca...of diagnosis , , MEMPHIS, Tenn., Nov. 27 /P...ildren,s Research Hospital have identified distinc...en with acute lymphoblastic leukemia (ALL) that ca...ning treatments for ALL relapse in children and, u...
(Date:11/26/2008)... Subjects , , FRANKLIN, Mass., Nov. 26 /PRN...in Board: PLCSF) announced today that it has recei...nistration (FDA) for its U.S. pivotal trial to stu...ystem(TM) and associated therapy in the preventio... The FDA also approved PLC,s request to expand th...
(Date:11/25/2008)...espondents against expanding statin use broadly in...LS, N.J., Nov. 25 JUPITER, a clini...rdiovascular risk of healthy patients with elevate...lder adults, according to a national poll directed...took part in the online poll conducted by medical ...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 1Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 2Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 3Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 4Breast Cancer Unchanged in Black Women Despite Drop in HRT Use 16891 1Breast Cancer Unchanged in Black Women Despite Drop in HRT Use 16891 2Breast Cancer Unchanged in Black Women Despite Drop in HRT Use 16891 3Nanodrop test tubes created with a flip of a switch 2902 1Nanodrop test tubes created with a flip of a switch 2902 2Covenant House Welcomes His Holiness Pope Benedict XVI 16888 1
...ts Success with Positive Phase IIa Clinical,Trial ...New Application of Key,Product in AM-Pharma,s Pipe...arma B.V., the,biopharmaceutical company developin...mmatory diseases, today announced the positive,cli...e (AP) trial,for patients with ulcerative colitis,...
...etts, July 08, 2007 /PRNewswire/ -- , - ENDORSE Gl...ment Hospital-Wide Strategies to Optimize VTE Mana... and Provide Appropriate,prophylaxis to Prevent VT...g hospital,patients and most of these at-risk pati...ccording to data from the international,ENDORSE (E...
Other Medicine Technology:AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 2International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 3International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 4
(Date:12/1/2008)...se, personality illnesses common, study shows , ...hiatric disorders are common among young adults in...report shows. , To reach this finding, U.S. res...dents, aged 19 to 25, who took part in the Nationa...itions. , The study found that 45.8 percent of ...
(Date:12/1/2008)...s with the agency,s goals, commitment and resource...-- Responding to criticism that it has done a poor...S. Food and Drug Administration released a report ... , Among the most important changes in 2008 was...hips with state and local health departments to pr...
(Date:12/1/2008)... the National Cancer Institute,s cancer registry h...xperience delayed or incomplete radiation treatmen...is suboptimal care can lead to worse outcomes. , ...College and colleagues found that among a national...ncer registry patients aged 65 and older, almost 1...
(Date:12/1/2008)... Dec. 1 Due to the urgent need to ... of AIDS/HIV research and clinical care, publisher...mentary access to all archival online issues of th...ber in honor of World AIDS Day. Free online access... www.liebertpub.com/apc ) and AIDS Research and ...
Breaking Medicine News(10 mins):Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2
... States is due to birth defects, a study has found...lyzed the medical records of babies under 10 days ...t, such as, pulmonary valve stenosis, happen to be...italization. The study, enabled by the U.S. Cente...
...n reported worldwide due to vaccination programmes...due to measles by 50%. But a sixty percent success...goal. Western Pacific Region stands first with a ...ath followed by 75% in Asia. Dr Lara Wolfson of W...
...showed reasonable resistance to Tamiflu, an antivi...ird flu.// This caused anxiety in the medical comm...rus strain called as 294S was first found in Vietn...in in Egypt reveals that it has spread outside Asi...
...ted annually in Thailand is an ongoing challenge f... to Somchai Pinyopornpaitch, deputy director-gener...have increased for several years despite health of...land is currently 50 per 100,000 people, with 90,0...
Other Medicine News:
...isticated lathing techniques, intrinsically permea...hinsite lenses feature a center thickness of just ... powered Thinsite lenses maintain a 30% decrease i...ue design eliminates stress points to reduce the c...
Lifestyle Gp is a simultaneous vision lens with patented multi-aspheric back surface. Through a series of front and back surface curves, the LifeStyle Gp delivers up to +3.00 diopters of add. Plus, i
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach.
Medicine Products: